16:10 EDT Neuphoria Therapeutics (NEUP) Inc trading halted, news pending
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NEUP:
- H.C. Wainwright biotech analysts hold an analyst/industry conference call
- Neuphoria Therapeutics: Strong Cash Position and Promising Pipeline Drive Buy Rating
- Neuphoria Therapeutics price target raised to $35 from $18 at Maxim
- Neuphoria Therapeutics completes target enrollment in Phase 3 AFFIRM-1 trial
- Neuphoria Therapeutics initiated with a Buy at Lucid Capital